D D S 2020 DIGITAL - Pulmonary Vascular Research Institute

Page created by Wade Manning
 
CONTINUE READING
D D S 2020 DIGITAL - Pulmonary Vascular Research Institute
P VRI
                                                                       Pulmonary Vascular
                                                                        Research Institute

 D D S 2020
                            DIGITAL                          Date // 24-29 June 2020

                                                             24-28 June: Release of recorded
                                                                         presentations
                                                             29 June:    15:00 BST
                                                                         Live webinar

PVRI Drug Discovery & Development Symposium on Pulmonary Hypertension
                                             // Paul Hassoun, Allan Lawrie & Anna Hemnes
D D S 2020 DIGITAL - Pulmonary Vascular Research Institute
PVRI
                                                                                                                                                             Pulmonary Vascular
                                                                                                                                                              Research Institute

  D D S 2020
                                   DIGITAL

                                                PVRI Drug Discovery & Development Symposium
                                                                   on Pulmonary Hypertension
                                                                              Welcome to our DDS 2020 Digital Online Symposium, which we hope you
                                                                                                   find informative and enjoyable in equal measure.
                                                                            In light of the global health and safety recommendations, we are delivering our Symposium
                                                                             in a digital format due to the current worldwide coronavirus pandemic. Presentations will
                                                                                    be released daily from 24-28 June 2020 and lead to a live webinar on 29 June 2020.
                                                                                  There is plenty of time allocated for Q&A and feedback during this live session and we
                                                                                                                                     encourage you all to join us online.
                                                                                                                                      Registration is free and open to all.

Our Scientific Planning Committee...

       Gérald Simonneau                  Marc Humbert              Ardeschir Ghofrani                               Steeve Provencher
       • Hopitaux Universitaires         • Université Paris-Sud,   • Justus-Liebig-University                       • University Institute of Cardiology
         Paris-Sud,                        France                    Giessen,                                         and Pneumology of Quebec,
         France                                                      Germany                                          Canada
D D S 2020 DIGITAL - Pulmonary Vascular Research Institute
PVRI
                                                                                                                                                                                                                                Pulmonary Vascular
                                                                                                                                                                                                                                 Research Institute

Our keynote speakers during the live webinar
on 29 June 2020 are...

                                                                                                                                                                                        D D S 2020
     Ardeschir Ghofrani                                                                                                   Kathryn Hall
     Presentation: // Clinical study of inhaled GB002 for treatment of WHO Group I pulmonary arterial                     Presentation: // Pharmacogenomics and placebo
                      hypertension (PAH) (NCT03926793)                                                                                     response in a randomised clinical
     Sponsor:      // Gossamer Bio                                                                                                         trials
     Talk:         // 15:00 - 15:20 BST                                                                                   Talk:         // 16:20 - 16:40 BST

                                                                                                                                                                                                                          DIGITAL
     Q&A:          // 15:20 - 15:40 BST                                                                                   Q&A:          // 16:40 - 17:00 BST
     Dr Ardeschir Ghofrani is Professor of Pulmonary Vascular Research at Justus-Liebig-University Giessen,               Dr. Kathryn Hall is Associate Molecular Biologist
     and Head of the Pulmonary Hypertension Division at the University Hospital in Giessen, Germany.                      and Assistant Professor in the Division of Preventive
     He leads a translational research group on development of new therapeutics for cardiopulmonary vascular              Medicine at Brigham and Women’s Hospital and
     disease and is a member of the steering committee of the Excellence Cluster Cardio-Pulmonary System                  Director of Placebo Genetics in the Program in Placebo
     (www.eccps.de). He is also a founding member of the Pulmonary Vascular Research Institute                            Studies hosted at Beth Israel Deaconess Medical Center.
     (www.pvrinstitute.org). He has participated in the development of several therapeutics for chronic lung diseases     After receiving her PhD in Microbiology and Molecular Genetics
     and pulmonary hypertension, including prostanoids, phosphodiesterase inhibitors, endothelin receptor                 from Harvard University she spent 10 years in the biotech industry
     antagonists, tyrosine kinase inhibitors and stimulators of the soluble guanylate cyclase. Professor Ghofrani has     tackling problems in drug discovery and development, first at Wyeth
     received four awards for investigations in pulmonary vascular science, is a Fellow of the European Respiratory       (now Pfizer) and then at Millennium Pharmaceuticals (now Takeda), where she
     Society (FERS) and a reviewer for several medical scientific journals. He has also received the Federal              became an Associate Director of Drug Development. Dr. Hall returned to Harvard Medical School in 2010,
     President’s Award for Innovation and Technology (Deutscher Zukunftspreis).                                           joining the Fellowship in Integrative Medicine at Beth Israel Deaconess Medical Center in 2012, and receiving
                                                                                                                          a Master’s in Public Health from Harvard T.H. Chan School of Public Health in 2014. Dr. Hall was the 2015
                                                                                                                          Harvard Catalyst Program for Faculty Development and Diversity Inclusion (PPFDD) faculty fellow and is the
                                                                                                                          2019 BWH Minority Faculty Career Development Awardee. Dr. Hall’s recent research has focused on
     David Badesch                                                                                                        catechol-O-methyltransferase (COMT), an enzyme that metabolizes catecholamines and estrogen and has
     Presentation: // A study of sotatercept for the treatment of pulmonary arterial hypertension                         pleiotropic effects in a broad set of diseases and treatments, including cardiovascular disease and cancer.
                      (PULSAR, NCT03496207)                                                                               Among her accomplishments is a landmark paper identifying COMT as one of the first genetic markers of
     Sponsor:      // Acceleron                                                                                           placebo response, a publication in JCI Insight on the placebo genetic network or placebome. She was recently
     Talk:         // 15:40 - 16:00 BST                                                                                   awarded a Radcliffe Exploratory Program grant which supported the groundbreaking Placebome in Clinical
     Q&A:          // 16:00 - 16:20 BST                                                                                   Trials and Medicine Conference in 2019. Her research has been the focus of numerous articles including
                                                                                                                          features on BBC and in Science, The Atlantic, New York Times, The Economist and Discover magazines.
     Dr. Badesch is a Professor of Medicine, in the Divisions of Pulmonary Sciences & Critical Care Medicine,             Dr. Hall also has a Masters in Documentary Film from Emerson College.
     and Cardiology, and Director of the Pulmonary Hypertension Program, at the University of Colorado.
     He has collaborated with dedicated clinical scientists on the Steering Committees (national and international)
     of clinical trials and registries conducted in the field of pulmonary hypertension. Dr. Badesch has authored or
     co-authored papers describing the results of clinical trials in the field, in the Annals of Internal Medicine, New
     England Journal of Medicine, Lancet, Journal of the American College of Cardiology, and CHEST. He has served
     as Chair of the Scientific Leadership Council of the Pulmonary Hypertension Association (PHA), Chair of the
     Pulmonary Circulation Assembly of the American Thoracic Society (ATS), and as a member the PHA and ATS
     Board(s) of Directors, as well as on the ATS Planning and Education Committees. Dr. Badesch helped to lead
     development of the ACCP/CHEST Medical Therapy Guidelines in 2004, and the updates to those guidelines
     published in 2007, 2014, and 2019. He received the Outstanding Physician Award from the PHA in 2002, the
     Outstanding Physician Award from the Colorado Thoracic Society in 2014, was inducted into the Colorado
     Pulmonary Hall of Fame in 2014, and received the American Thoracic Society Public Advisory Roundtable
     William J. Martin II Distinguished Achievement Award in 2015. He has been listed among the Best Doctors in
     America 2001-present, and is a Distinguished Advisor to the Pulmonary Hypertension Association’s Scientific
     Leadership Council. Dr. Badesch has also been an active member of the community, leading an effort to make
     all public schools in Colorado tobacco-free. In recognition of his service, he has received the CHEST
     Foundation’s Community Service Award (one of the first two recipients, in 1998). More recently, he has assisted
     in the care of patients with pulmonary hypertension in South Africa, as well as the development of clinical
     guidelines, a registry, and centers for pulmonary hypertension care there.
D D S 2020 DIGITAL - Pulmonary Vascular Research Institute
PVRI
                                                                                                                                                                                                 Pulmonary Vascular
                                                                                                                                                                                                  Research Institute

Our moderators during the live webinar on
29 June 2020 are...

                                                                                                                                                                                         D D S 2020
     Paul Hassoun                                                                                                    Allan Lawrie
     Dr Paul M Hassoun is a Professor of Medicine at the Johns Hopkins University School of Medicine in the          Allan Lawrie is a Professor of Translational
     USA. His areas of clinical expertise include pulmonary disease and critical care medicine.                      Cardiopulmonary Science and British Heart
     Dr Hassoun earned his MD from the Faculté de Médecine Lariboisière-Saint Louis (Paris VII, France) and          Foundation Senior Basic Science Research
     completed a residency in Internal Medicine at Brigham and Women’s Hospital and a Pulmonary and Critical         Fellow in the Department of Infection,

                                                                                                                                                                                               DIGITAL
     Care fellowship at Massachusetts General Hospital, both at Harvard Medical School, Boston MA.                   Immunity & Cardiovascular Disease at the
                                                                                                                     University of Sheffield.
     Dr Hassoun serves as the Director of the Pulmonary Hypertension Programme, a large clinical programme
     dedicated to the diagnosis and treatment, in a multidisciplinary fashion, of all five disease groups from the   Allan’s research has focused on identifying a key
     World Classification of PH.                                                                                     role for osteoprotegerin/TRAIL pathway in the
                                                                                                                     pathogenesis of PAH. Supported by Fellowships and
     Over the past two decades, Dr Hassoun has led programmatic efforts for clinical and basic research in PH.
                                                                                                                     grants from the MRC and BHF he has recently
     Dr Hassoun’s research interests include pulmonary arterial hypertension (PAH) with a focus on highly
                                                                                                                     developed a novel human therapeutic antibody targeting
     translational research to understand the complex pathobiology of scleroderma-associated PAH, and acute
                                                                                                                     this pathway.
     lung injury. He is a member of numerous professional organisations, including the American Thoracic Society,
     the European Respiratory Society, and the American Heart Association.                                           Allan also works closely with clinical colleagues locally,
                                                                                                                     nationally and internationally to identify biomarkers and utilise
     Dr Hassoun served as PVRI President during 2018/19.
                                                                                                                     multi-omic approaches for molecular phenotyping, identifying
                                                                                                                     novel disease mechanisms and drug targets.

     Anna Hemnes
     Associate Professor and Assistant Director Pulmonary Vascular Centre, Vanderbilt University Medical
     Centre, USA.
     Dr Anna Hemnes is a translational physician-scientist with a research focus on the role of altered metabolism
     in pulmonary vascular disease. Her basic research is on the effect of BMPR2 mutation on insulin-mediated
     intracellular signalling in the pulmonary vasculature and the right ventricle.
     Dr Hemnes’ clinical research interests include the role of insulin resistance and metabolic syndrome in human
     pulmonary vascular disease with a focus on genetic susceptibility to these conditions, and deep molecular
     phenotyping of pulmonary vascular disease.
D D S 2020 DIGITAL - Pulmonary Vascular Research Institute
Scientific Programme                                                                                        We are extremely grateful to all the presenters who
                                                                                                               have agreed to provide a recording of their talk.
                                                                                                                        These presentations will be released from

Featured presentation releases...
                                                                                                                               24-28 June and can be accessed via
                                                                                                             https://pvrinstitute.org/en/professionals/learning/
24-28 June 2020

24 June

                                                                                                                                 D D S 2020
Tamoxifen therapy to treat pulmonary arterial hypertension (T3PAH) (NCT03528902)
Presenter: // Eric Austin VANDERBILT UNIVERSITY, USA
Sponsor: // Vanderbilt University Medical Center

IV iron replacement for iron deficiency in idiopathic pulmonary arterial hypertension (IPAH) patients
(NCT01447628)
                                                                                                                                                   DIGITAL
Sponsor: // Imperial College London
Presenter: // Luke Howard IMPERIAL COLLEGE LONDON, UK

25 June

Right heart III Study: Right ventricular haemodynamic evaluation and response to treatment (NCT03362047)
Presenter: // Khodr Tello JUSTUS-LIEBIG-UNIVERSITY GIESSEN, GERMANY
Sponsor: // Justus-Liebig-University Giessen

Actigraphy as a new endpoint in PAH trials
Sponsor: // Actelion
Presenter: // Ioana Preston TUFTS UNIVERSITY SCHOOL OF MEDICINE, USA

26 June

BPA: Where does it come from, where are we and where are we going?
Presenter: // Hiromi Matsubara NATIONAL HOSPITAL ORGANIZATION OKAYAMA MEDICAL CENTER, JAPAN

A novel unidirectional-valved shunt approach for end-stage pulmonary arterial hypertension:
Early experience in adolescents and adults
Presenter: // Erika Rosenzweig COLUMBIA UNIVERSITY MEDICAL CENTER, USA
Sponsor: // Columbia University

27 June

PADN-5: Pulmonary arterial denervation in patients with pulmonary hypertension associated with left heart
failure (NCT02220335)
Presenter: // Shao-Liang Chen NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY, CHINA
Sponsor: // Nanjing Healthy Bureau & National Science Foundation of China

28 June
Implantable devices to improve pulmonary circulation compliance
Presenters: // John Scandurra ARIA CV, USA & Irene Lang MEDICAL UNIVERSITY OF VIENNA, AUSTRIA
Sponsor: // Aria CV
D D S 2020 DIGITAL - Pulmonary Vascular Research Institute
Scientific Programme
                                                                                                                                 We are anticipating a very large audience for this event.
                                                                                                                              If not all questions can be answered on the day, please be rest

Our live webinar...
                                                                                                                                   assured that all comments, questions and answers will be
                                                                                                                               published and circulated to all participants after the webinar.

29 June 2020

                                                                    NOTE: All times indicated are British Summer Time (BST)

15:00

                                                                                                                                                            D D S 2020
Clinical study of inhaled GB002 for treatment of WHO Group I pulmonary arterial
hypertension (PAH) (NCT03926793)                                                                         15:00 - 15:20 BST

                                                                                                                                                                               DIGITAL
Presenter: // Ardeschir Ghofrani JUSTUS-LIEBIG-UNIVERSITY GIESSEN, GERMANY
Sponsor: // Gossamer Bio

Q&A session                                                                                              15:20 - 15:40 BST

15:40

A study of sotatercept for the treatment of pulmonary arterial hypertension
(PULSAR, NCT03496207)                                                                                    15:40 - 16:00 BST

Presenter: // David Badesch UNIVERSITY OF COLORADO, USA
Sponsor: // Acceleron

Q&A session                                                                                              16:00 - 16:20 BST

16:20

Pharmacogenomics and placebo response in a randomised clinical trials                                    16:20 - 16:40 BST

Presenter: // Kathryn Hall BRIGHAM AND WOMEN’S HOSPITAL, HARVARD MEDICAL SCHOOL, USA

Q&A session                                                                                              16:40 - 17:00 BST
D D S 2020 DIGITAL - Pulmonary Vascular Research Institute
Step into the PVRI
Digital Clinic...
...and claim CME credits.

                                                          PVRI
                                                           Pulmonary Vascular
                                                            Research Institute

                                          www.pvrinstitute.org

                            The PVRI is a Registered Charity in the UK, No: 1127115.
                            Disclaimer: This programme and its contents are correct at the time of printing.
D D S 2020 DIGITAL - Pulmonary Vascular Research Institute D D S 2020 DIGITAL - Pulmonary Vascular Research Institute D D S 2020 DIGITAL - Pulmonary Vascular Research Institute
You can also read